Kin-Hung Peony Yu

Dr. Kin-Hung Peony Yu joined Apollomics in 2021 as Chief Medical Officer. Dr. Peony Yu will be providing leadership to R&D and be primarily responsible for clinical development of the Company’s products. She has over 25 years of experience in pharmaceutical leadership, patient care and drug development, with expertise in clinical regulatory strategy and execution of clinical programs of innovative biopharmaceuticals.

Previously, Dr. Yu worked for FibroGen, Inc. (NASDAQ: FGEN) as a vice president until her designation as CMO. She also served as the vice president and head of clinical research at Anesiva, Inc., formerly known as Corgentech, Inc., (NASDAQ: ANSV); a director of clinical development at ALZA Corporation, a subsidiary of Johnson & Johnson (NYSE: JNJ), and held roles of increasing responsibility in clinical development at Pain Therapeutics, Inc. (now known as Cassava Sciences, Inc. (NASDAQ: SAVA)) and at Elan Corporation plc (now known as Perrigo Company plc (NYSE: PRGO)). She obtained an M.D. degree from the University of California, Davis School of Medicine, in the United States. She completed her residency training at Stanford University School of Medicine in the U.S. Dr. Peony Yu has authored or co-authored 12 peer-reviewed publications. Dr. Peony Yu holds a medical license registered in California.

Dr. Peony Yu is an independent nonexecutive director at STAAR Surgical Company (NASDAQ: STAA).